Safety evaluation of cryoablation device ICS4 in cryoablation of lung tumors
Phase 1
Not yet recruiting
- Conditions
- lung tumors
- Registration Number
- JPRN-UMIN000006118
- Lead Sponsor
- School of Medicine, Keio University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
5.1.7. Coagulopathies. 5.1.8. Bleeding tendencies. 5.1.9. Uncontrolled infection. 5.1.10. Uncontrolled brain or medullary metastasis. 5.1.11. Unable to tolerate general anesthesia. 5.1.12. Difficulties in communication. 5.1.13. Excluded by the attending physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety
- Secondary Outcome Measures
Name Time Method efficacy
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie cryoablation's efficacy in lung tumor treatment?
How does cryoablation device ICS4 compare to standard-of-care therapies for lung tumors in terms of safety and effectiveness?
Are there specific biomarkers that can predict patient response to ICS4 cryoablation for lung tumors?
What are the known adverse events associated with ICS4 cryoablation in lung tumor patients and how are they managed?
What are the potential combination approaches involving ICS4 cryoablation for enhanced lung tumor treatment outcomes?